Felbamate hydrate
Modify Date: 2025-08-26 13:32:24
Felbamate hydrate structure
|
Common Name | Felbamate hydrate | ||
|---|---|---|---|---|
| CAS Number | 1177501-39-1 | Molecular Weight | 256.255 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C11H16N2O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Felbamate hydrateFelbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .Target: NMDA ReceptorFelbamate (marketed under the brand name Felbatol by MedPointe) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy.Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptor of relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain. |
| Name | Felbamate hydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .Target: NMDA ReceptorFelbamate (marketed under the brand name Felbatol by MedPointe) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy.Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptor of relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C11H16N2O5 |
|---|---|
| Molecular Weight | 256.255 |
| Exact Mass | 256.105927 |
| Storage condition | 2-8℃ |
| 2-Phenyl-1,3-propanediyl dicarbamate hydrate (1:1) |
| 1,3-Propanediol, 2-phenyl-, dicarbamate, hydrate (1:1) |
| MFCD28168059 |